
One of the challenges faced by the pharmaceutical industry is the phenomenon of large-scale falsification of medicinal products. There are many consequences of this phenomenon, the key one being the threat to product safety and, consequently, the threat to the health and life of patients.
According to the World Health Organization (WHO), the value of the global market for falsified medicinal products has reached USD 430 billion annually [AP, Pharmaceutical Companies Fund Interpol Fight Against Fake Prescription Drugs, March 2013]. Illegal medicines are a problem for both developing and highly developed countries, where lifestyle-related drugs are also being counterfeited [Problemy Kryminalistyki 263 (January – March) 2009]. Furthermore, as data from the WHO and Interpol show, 30% of medicines confiscated in the European Union come from India, and another 30% from the United Arab Emirates.
Falsified Medicines Directive
Problems related to the falsification of medicinal products are the genesis of Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011, amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products. This directive is colloquially known as the Falsified Medicines Directive, and according to it, the medicine packaging should contain: an anti-tampering device and a unique identifier. In addition to the characteristics of the medicinal products themselves, Directive 2011/62/EU defines the basic assumptions for the creation and operation of a database that will enable immediate verification of product authenticity at the points of dispensing. The requirement for so-called serialization will cover: prescription medicines (Rx), excluding products on the so-called white list; and non-prescription medicines (OTC) that are on the so-called black list. Furthermore, on 9 February 2016, Commission Delegated Regulation (EU) 2016/161 was published, which strictly specifies the structure of the so-called unique identifier. This identifier should consist of the following elements:
- a code enabling the recognition of at least the name, common name, pharmaceutical form, strength, pack size, and pack type of the medicinal product (“product code”)
- a sequence of numeric or alphanumeric characters of up to 20 characters, generated based on an algorithm (“serial number”)
- batch number
- expiry date.
The unique identifier should be presented in a Data Matrix barcode compliant with the ISO 16022:2006 standard. This code should have a print quality rated at 1.5 in accordance with the ISO 15415:2011 standard. It is worth adding that the new method of marking medicinal products, as well as the operating database, should be launched on 9 February 2019, i.e., 3 years from the moment the regulation was published.
The article contains 7150 characters.
Source: Logistyka Magazine








